CN Patent

CN113018258A — 包含对乙酰氨基酚和布洛芬的水性制剂

Assigned to Herolis Pharmaceutical Co ltd · Expires 2021-06-25 · 5y expired

What this patent protects

本发明涉及pH 6.3‑7.3的布洛芬和对乙酰氨基酚水性组合物及其用途。本发明涉及制备布洛芬和对乙酰氨基酚的组合产品的方法。本发明涉及所述组合物用作药物，特别是用于治疗疼痛和/或炎症的药物，特别是用于通过静脉内注射施用所述组合物。

USPTO Abstract

本发明涉及pH 6.3‑7.3的布洛芬和对乙酰氨基酚水性组合物及其用途。本发明涉及制备布洛芬和对乙酰氨基酚的组合产品的方法。本发明涉及所述组合物用作药物，特别是用于治疗疼痛和/或炎症的药物，特别是用于通过静脉内注射施用所述组合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN113018258A
Jurisdiction
CN
Classification
—
Expires
2021-06-25
Drug substance claim
No
Drug product claim
No
Assignee
Herolis Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.